Stock price movement
On April 12, Viking Therapeutics (VKTX) closed at $9.35, 6.22% lower than its previous closing price, 153.39% higher than its 52-week low of $3.69, and 61.04% below its 52-week high of $24.00. The company’s market capitalization is $653.47 million, and its PB (price-to-book) and PC (price-to-cash) ratios are 2.25x and 2.17x, respectively. Since its last earnings release on March 13, Viking Therapeutics stock has increased by 13.33% from $8.25 on March 13 to $9.35 on April 12.
Ready to put your morning scrolling to use? Sign up for Bagels & Stox, our witty take on the top market and investment news straight to your inbox! Whether you’re a serious investor or just want to be informed, Bagels & Stox will be your favorite email.
On April 12, Enanta Pharmaceuticals (ENTA) closed at $92.20, 0.47% higher than its previous closing price, 43.87% higher than its 52-week low of $64.08, and 27.84% below its 52-week high of $127.77. The company’s market capitalization is $1.79 billion, and its PE, PS (price-to-sales), PB, and PC ratios are 22.35x, 7.51x, 4.20x, and 5.18x, respectively.
Since its last earnings release on February 6, Enanta Pharmaceuticals stock has increased by 10.00% from $83.80 on February 6 to $92.20 on April 12.
Analysts’ recommendations and target price
Wall Street analysts expect an upside potential of 188.77% for Viking Therapeutics based on the company’s closing price on April 12. Analysts reduced the company’s 12-month consensus target price from $29.79 in February to $26.94 in March but have raised it to $27.00 in April. The current consensus analyst recommendation for the stock is a “buy.”
Of the nine analysts covering Viking Therapeutics, three have rated the company as a “strong buy,” and six have rated it as a “buy.” Wall Street analysts expect an upside potential of 9.00% for Enanta Pharmaceuticals based on the company’s closing price on April 12. Analysts have raised the company’s 12-month consensus target price from $99.50 in February to $100.50 in March and April. The current consensus analyst recommendation for the stock is a “hold.”
Of the seven analysts covering Enanta Pharmaceuticals, two have rated the company as “buy,” and five have rated it as a “hold.”